Synchronous Overexpression of Epidermal Growth Factor Receptor and HER2-neu Protein Is a Predictor of Poor Outcome in Patients with Stage I Non-Small Cell Lung Cancer

Clinical Cancer Research

Volumn 10, Issue 1 I, 2004, Pages 136-143

  Onn, Amir ^a   Correa, Arlene M ^a   Gilcrease, Michael ^a   Isobe, Takeshi ^a   Massarelli, Erminia ^a   Bucana, Corazon D ^a   O'Reilly, Michael S ^a   Hong, Waun K ^a   Fidler, Isaiah J ^a   Putnam, Joe B ^a   Herbst, Roy S ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRANSFORMING GROWTH FACTOR ALPHA;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER RECURRENCE; CANCER SURGERY; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SQUAMOUS CELL CARCINOMA;

ADENOCARCINOMA; ADENOCARCINOMA, BRONCHIOLO-ALVEOLAR; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PHOSPHORYLATION; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE; TRANSFORMING GROWTH FACTOR ALPHA;

EID: 1642453746     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-0373-3     Document Type: Article

References (42)

1. Carney, D. N. Lung cancer-time to move on from chemotherapy. N. Engl. J. Med., 346: 126-128, 2002.
2. Mountain, C. F. Revisions in the International System for Staging Lung Cancer. Chest, 111: 1710-1717, 1997.
3. Slebos, R. J., Kibbelaar, R. E., Dalesio, O., Kooistra, A., Stam, J., Meijer, C. J., Wagenaar, S. S., Vanderschueren, R. G., van Zandwijk, N., Mooi, W. J., et al. K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. N. Engl. J. Med., 323: 561-565, 1990.
4. Herbst, R. S., Yano, S., Kuniyasu, H., Khuri, F. R., Bucana, C. D., Guo, F., Liu, D., Kemp, B., Lee, J. J., Hong, W. K., and Fidler, I. J. Differential expression of E-cadherin and type IV collagenase genes predicts outcome in patients with stage I non-small cell lung carcinoma. Clin. Cancer Res., 6: 790-797, 2000.
5. Pezzella, F., Turley, H., Kuzu, I., Tungekar, M. F., Dunnill, M. S., Pierce, C. B., Harris, A., Gatter, K. C., and Mason, D. Y. bcl-2 protein in non-small-cell lung carcinoma. N. Engl. J. Med., 329: 690-694, 1993.
6. Khuri, F. R., Lotan, R., Kemp, B. L., Lippman, S. M., Wu, H., Feng, L., Lee, J. J., Cooksley, C. S., Parr, B., Chang, E., Walsh, G. L., Lee, J. S., Hong, W. K., and Xu, X. C. Retinoic acid receptor-β as a prognostic indicator in stage I non-small-cell lung cancer. J. Clin. Oncol., 18: 2798-2804, 2000.
7. Lee, J. S., Ro, J. Y., Sahin, A. A., Hong, W. K., Brown, B. W., Mountain, C. F., and Hittelman, W. N. Expression of blood-group antigen A - a favorable prognostic factor in non-small-cell lung cancer. N. Engl. J. Med., 324: 1084-1090, 1991.
8. Huang, S. M., and Harari, P. M. Epidermal growth factor receptor inhibition in cancer therapy: biology, rationale and preliminary clinical results. Investig. New Drugs, 17: 259-269, 1999.
9. Nicholson, R. I., Gee, J. M., and Harper, M. E. EGFR and cancer prognosis. Eur. J. Cancer, 37: S9-S15, 2001.
10. Prenzel, N., Fischer, O. M., Streit, S., Hart, S., and Ullrich, A. The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification. Endocr. Relat. Cancer, 8: 11-31, 2001.
11. Mendelsohn, J. Targeting the epidermal growth factor receptor for cancer therapy. J. Clin. Oncol., 20: 1S-13S, 2002.
12. Franklin, W. A., Veve, R., Hirsch, F. R., Helfrich, B. A., and Bunn, P. A., Jr. Epidermal growth factor receptor family in lung cancer and premalignancy. Semin Oncol., 29: 3-14, 2002.
13. Hendler, F. J., and Ozanne, B. W. Human squamous cell lung cancers express increased epidermal growth factor receptors. J. Clin. Investig., 74: 647-651, 1984.
14. Hirsch, F. R., Franklin, W. A., Veve, R., Varella-Garcia, M., and Bunn, P. A., Jr. HER2/neu expression in malignant lung tumors. Semin. Oncol., 29: 51-58, 2002.
15. Pinkas-Kramarski, R., Soussan, L., Waterman, H., Levkowitz, G., Alroy, I., Klapper, L., Lavi, S., Seger, R., Ratzkin, B. J., Sela, M., and Yarden, Y. Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. EMBO J., 15: 2452-2467, 1996.
16. Graus-Porta, D., Beerli, R. R., Daly, J. M., and Hynes, N. E. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J., 16: 1647-1655, 1997.
17. Brabender, J., Danenberg, K. D., Metzger, R., Schneider, P. M., Park, J., Salonga, D., Holscher, A. H., and Danenberg, P. V. Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer is correlated with survival. Clin. Cancer Res., 7: 1850-1855, 2001.
18. Tateishi, M., Ishida, T., Kohdono, S., Hamatake, M., Fukuyama, Y., and Sugimachi, K. Prognostic influence of the co-expression of epidermal growth factor receptor and c-erbB-2 protein in human lung adenocarcinoma. Surg. Oncol., 3: 109-113, 1994.
19. Lai, W. W., Chen, F. F., Wu, M. H., Chow, N. H., Su, W. C., Ma, M. C., Su, P. F., Chen, H., Lin, M. Y., and Tseng, Y. L. Immunohistochemical analysis of epidermal growth factor receptor family members in stage I non-small cell lung cancer. Ann. Thorac. Surg., 72: 1868-1876, 2001.
20. Fontanini, G., De Laurentiis, M., Vignati, S., Chine, S., Lucchi, M., Silvestri, V., Mussi, A., De Placido, S., Tortora, G., Bianco, A. R., Gullick, W., Angeletti, C. A., Bevilacqua, G., and Ciardiello, F. Evaluation of epidermal growth factor-related growth factors and receptors and of neoangiogenesis in completely resected stage I-IIIA non-small-cell lung cancer: amphiregulin and microvessel count are independent prognostic indicators of survival. Clin. Cancer Res., 4: 241-249, 1998.
21. Jacobs, T. W., Gown, A. M., Yaziji, H., Barnes, M. J., and Schnitt, S. J. Specificity of HercepTest in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system. J. Clin. Oncol., 17: 1983-1987, 1999.
22. Kaplan, E. L., and Meier, P. Nonparametric estimation from incomplete observation. J. Am. Stat. Assoc., 53: 457-481, 1958.
23. Brandt, B. H., Roetger, A., Dittmar, T., Nikolai, G., Seeling, M., Merschjann, A., Nofer, J. R., Dehmer-Moller, G., Junker, R., Assmann, G., and Zaenker, K. S. c-erbB-2/EGFR as dominant heterodimerization partners determine a motogenic phenotype in human breast cancer cells. FASEB J., 13: 1939-1949, 1999.
24. Moasser, M. M., Basso, A., Averbuch, S. D., and Rosen, N. The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells. Cancer Res., 61: 7184-7188, 2001.
25. Albanell, J., Rojo, F., Averbuch, S., Feyereislova, A., Mascaro, J. M., Herbst, R., LoRusso, P., Rischin, D., Sauleda, S., Gee, J., Nicholson, R. I., and Baselga, J. Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. J. Clin. Oncol., 20: 110-124, 2002.
26. Herbst, R. S., Maddox, A. M., Rothenberg, M. L., Small, E. J., Rubin, E. H., Baselga, J., Rojo, F., Hong, W. K., Swaisland, H., Averbuch, S. D., Ochs, J., and LoRusso, P. M. Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial. J. Clin. Oncol., 20: 3815-3825, 2002.
27. Onn, A., Killion, J. J., O'Reilly, M., and al., e. Development of an orthotopic model for human lung cancer to evaluate therapeutic efficacy of receptor tyrosine kinase inhibitors. Proc. Am. Assoc. Cancer Res., 43: 785, 2002.
28. Holt, S. J., Alexander, P., Inman, C. B., and Davies, D. E. Ligand-induced translocation of epidermal growth factor receptor to the nucleus of NR6/HER fibroblasts is serum dependent. Exp. Cell Res., 217: 554-558, 1995.
29. Lin, S. Y., Makino, K., Xia, W., Matin, A., Wen, Y., Kwong, K. Y., Bourguignon, L., and Hung, M. C. Nuclear localization of EGF receptor and its potential new role as a transcription factor. Nat. Cell Biol., 3: 802-808, 2001.
30. Mooi, W. J. Common lung cancers. In: P. S. Harsleton (ed.), Pathology of the Lung, pp. 1009-1064. New York, NY: McGraw Hill, Inc., 1996.
31. O'Byrne, K. J., Cox, G., Swinson, D., Richardson, D., Edwards, J. G., Lolljee, J., Andi, A., Koukourakis, M. I., Giatromanolaki, A., Gatter, K., Harris, A. L., Waller, D., and Jones, J. L. Towards a biological staging model for operable non-small cell lung cancer. Lung Cancer, 34: S83-S89, 2001.
32. D'Amico, T. A. Molecular biologic substaging of non-small cell lung cancer. J. Thorac. Cardiovasc. Surg., 123: 409-410, 2002.
33. Volm, M., Koomagi, R., Mattern, J., and Efferth, T. Expression profile of genes in non-small cell lung carcinomas from long-term surviving patients. Clin. Cancer Res., 8: 1843-1848, 2002.
34. Beer, D. G., Kardia, S. L., Huang, C. C., Giordano, T. J., Levin, A. M., Misek, D. E., Lin, L., Chen, G., Gharib, T. G., Thomas, D. G., Lizyness, M. L., Kuick, R., Hayasaka, S., Taylor, J. M., Iannettoni, M. D., Orringer, M. B., and Hanash, S. Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat. Med., 8: 816-824, 2002.
35. Almand, B., and Carbone, D. P. Biological considerations in lung cancer. Cancer Treat. Res., 105: 1-30, 2001.
36. Herbst, R. S., and Kies, M. S. ZD1839 (Iressa(TM)) in non-small cell lung cancer. Oncologist, 7: 9-15, 2002.
37. Fukuoka, M., Yano, S., Giaccone, G., Tamura, T., Nakagawa, K., Douillard, J. Y., et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J. Clin. Oncol., 12: 2237-2246, 2003.
38. Kris, M. G., Natale, R. B., Herbst, R. S., Lynch, T. J., Jr., Prager, D., Belani, C. P., et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA, 16: 2149-2158, 2003.
39. Zinner, R. G., Kim, J., and Herbst, R. S. Non-small cell lung cancer clinical trials with trastuzumab: their foundation and preliminary results. Lung Cancer, 37: 17-27, 2002.
40. Baker, C. H., Kedar, D., McCarty, M. F., Tsan, R., Weber, K. L., Bucana, C. D., and Fidler, I. J. Blockade of epidermal growth factor receptor signaling on tumor cells and tumor-associated endothelial cells for therapy of human carcinomas. Am. J. Pathol., 161: 929-938, 2002.
41. Franklin, W. A., Gumerlock, P. H., Crowley, J., Chansky, K., West, H. J., and Gandara, D. R. EGFR, HER2 and ERB-B pathway activation in bronchioloalveolar carcinoma (BAC): Analysis of SWOG 9417 and lung SPORE tissue samples. Proc. Am. Soc. Clin. Oncol., 22: 620, 2003.
42. Miller, V. A., Patel, J., Shah, N., Kris, M. G., Tyson, L., Pizzo, B., Zakowski, M., Memoli, N., Sandler, A., and Johnson, D. H. The epidermal growth factor receptor tyrosine kinase inhibitor erlotinib (OSI-774) shows promising activity in patients with bronchioloalveolar cell carcinoma (BAC): Preliminary results of a phase 11 trial. Proc. Am. Soc. Clin. Oncol., 22: 619, 2003.